Elsevier

Fertility and Sterility

Volume 93, Issue 7, 1 May 2010, Pages 2330-2336
Fertility and Sterility

Recurrent pregnancy loss
Anti-β2-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss

https://doi.org/10.1016/j.fertnstert.2009.01.089Get rights and content
Under an Elsevier user license
open archive

Objective

To evaluate the role of anti-β2-glycoprotein-I (anti-β2GPI-ab) and anti-phosphatidylserine (aPS-ab) antibodies as a risk factor in both recurrent miscarriage (RM) and unexplained fetal losses (UFL).

Design

Retrospective, cohort study.

Setting

Vall d'Hebron University Hospital, Barcelona, Spain.

Patient(s)

122 pregnant women divided in two groups: study group of 54 women with RM and/or UFL and control group of 68 pregnant without RM history.

Intervention(s)

Analysis of lupus anticoagulant, anticardiolipin antibodies, and anti-β2GP1 and aPS antibodies.

Main Outcome Measure(s)

Comparison of aPL antibody between groups.

Result(s)

The prevalence of aPL positive results was 8 out of 54 (14.8%) in the study group and 3 out of 68 (4.41%) in the controls. In the RM subgroup, the prevalence was 3 out of 25 (12%) versus 3 out of 68 (4.4%), and 7 out of 34 (20.6%) versus 3 out of 68 (4.4%) in UFL subgroup. As a whole, the prevalence of anti-β2GP1-ab in the RM/UFL group showed a difference compared with controls but not aPS-ab. In the RM women, anti-β2GP1-ab was positive in 3 out of 25 (12%) versus 1 out of 68 (1.5%) in controls and in 4 out of 34 versus 0 out of 68 cases in women with UFL. In the RM subgroup, aPS-ab was positive in 1 out of 25 (4%) versus 2 out of 68 (2.9%) in control group and in 3 out of 34 versus 2 out of 68 cases in women with UFL.

Conclusion(s)

Our results suggest that anti-β2GP1-ab but not aPS-ab is related to RM/UFL and should be considered as a pregnancy-loss risk factor.

Key Words

Antiphospholipid syndrome
antiphospholipid antibodies
anti-β2GP1 antibodies
anti-cofactor syndrome
anti-phosphatidylserine
pregnancy loss
recurrent miscarriage

Cited by (0)

J.A-R. has nothing to disclose. R.F-O. has nothing to disclose. M.J.R-A. has nothing to disclose. I.F-C. has nothing to disclose. L.C-R. has nothing to disclose. M.V-T. has nothing to disclose.

Supported by ORGENTEC Diagnostika GmbH, Mainz, Germany, which provided the specific reagents for aPL analyses.